トレプロスチニルパルミチル新薬の考察と市場予測（2032年）

当レポートでは、トレプロスチニルパルミチルの主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）について調査分析し、作用機序、用法と用量、研究開発活動についての考察や、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 肺動脈性肺高血圧症におけるトレプロスチニルパルミチルの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新しい治療法）

第5章 トレプロスチニルパルミチル市場の評価

• 肺動脈性肺高血圧症におけるトレプロスチニルパルミチルの市場の見通し
• 主要7市場の分析
  • 主要7市場の肺動脈性肺高血圧症向けトレプロスチニルパルミチルの市場規模
• 市場の分析：国別
  • 米国の肺動脈性肺高血圧症向けトレプロスチニルパルミチルの市場規模
  • ドイツの肺動脈性肺高血圧症向けトレプロスチニルパルミチルの市場規模
  • 英国の肺動脈性肺高血圧症向けトレプロスチニルパルミチルの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Treprostinil palmitil: Clinical Trial Description, 2022
• Table 2: Treprostinil palmitil: General Description
• Table 3: Competitive Landscape ( Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5:Treprostinil palmitil Market Size in the 7MM, in USD million (2019-2032)
• Table 6:Treprostinil palmitil Market Size in the United States, in USD million (2019-2032)
• Table 7:Treprostinil palmitil Market Size in Germany, in USD million (2019-2032)
• Table 8:Treprostinil palmitil Market Size in France, in USD million (2019-2032)
• Table 9:Treprostinil palmitil Market Size in Italy, in USD million (2019-2032)
• Table 10:Treprostinil palmitil Market Size in Spain, in USD million (2019-2032)
• Table 11:Treprostinil palmitil Market Size in the United Kingdom, in USD million (2019-2032)
• Table 12:Treprostinil palmitil Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Market Size of Treprostinil palmitil in the 7MM, in USD million (2019-2032)
• Figure 2: Market Size of Treprostinil palmitil in the United States, in USD million (2019-2032)
• Figure 3: Market Size of Treprostinil palmitil in Germany, in USD million (2019-2032)
• Figure 4: Market Size of Treprostinil palmitil in France, in USD million (2019-2032)
• Figure 5: Market Size of Treprostinil palmitil in Italy, in USD million (2019-2032)
• Figure 6: Market Size of Treprostinil palmitil in Spain, in USD million (2019-2032)
• Figure 7: Market Size of Treprostinil palmitil in the United Kingdom, in USD million (2019-2032)
• Figure 8:Market Size of Treprostinil palmitil in Japan, in USD million (2019-2032)

"Treprostinil palmitil Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about Treprostinil palmitil for Pulmonary Arterial Hypertension in the 7MM. A detailed picture of the Treprostinil palmitil for Pulmonary Arterial Hypertension in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Treprostinil palmitil for Pulmonary Arterial Hypertension. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Treprostinil palmitil market forecast, analysis for Pulmonary Arterial Hypertension in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Pulmonary Arterial Hypertension.

Drug Summary:

Treprostinil palmitil (TP) is a prodrug of treprostinil (TRE), a pulmonary vasodilator that has been previously formulated for inhaled administration via a nebulizer. TP demonstrates a sustained presence in the lungs with reduced systemic exposure and prolonged inhibition of hypoxia-induced pulmonary vasoconstriction in vivo.

The major pharmacological actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In addition to treprostinil's direct vasodilatory effects, it also inhibits inflammatory cytokines. As a synthetic analogue of prostacyclin, it binds to the prostacyclin receptor, which subsequently induces the aforementioned downstream effects.

Treprostinil palmitil (TP) is administered by oral inhalation using a Plastiape capsule-based dry powder inhaler.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Treprostinil palmitil description, mechanism of action, dosage and administration, research and development activities in Pulmonary Arterial Hypertension.
• Elaborated details on Treprostinil palmitil regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Treprostinil palmitil research and development activity in Pulmonary Arterial Hypertension details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Treprostinil palmitil.
• The report contains forecasted sales of Treprostinil palmitil for Pulmonary Arterial Hypertension till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Pulmonary Arterial Hypertension.
• The report also features the SWOT analysis with analyst views for Treprostinil palmitil in Pulmonary Arterial Hypertension.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Treprostinil palmitil Analytical Perspective by DelveInsight

• In-depth Treprostinil palmitil Market Assessment

This report provides a detailed market assessment of Treprostinil palmitil in Pulmonary Arterial Hypertension in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data for Treprostinil palmitil.

• Treprostinil palmitil Clinical Assessment

The report provides the clinical trials information of Treprostinil palmitil for Pulmonary Arterial Hypertension covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Pulmonary Arterial Hypertension is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Treprostinil palmitil dominance.
• Other emerging products for Pulmonary Arterial Hypertension are expected to give tough market competition to Treprostinil palmitil and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Treprostinil palmitil in Pulmonary Arterial Hypertension.
• Our in-depth analysis of the forecasted sales data of Treprostinil palmitil will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Treprostinil palmitil in Pulmonary Arterial Hypertension.

Key Questions

• What is the product type, route of administration and mechanism of action of Treprostinil palmitil?
• What is the clinical trial status of the study related to Treprostinil palmitil in Pulmonary Arterial Hypertension and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Treprostinil palmitil development?
• What are the key designations that have been granted to Treprostinil palmitil for Pulmonary Arterial Hypertension?
• What is the forecasted market scenario of Treprostinil palmitil for Pulmonary Arterial Hypertension?
• What are the forecasted sales of Treprostinil palmitil in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Pulmonary Arterial Hypertension and how are they giving competition to Treprostinil palmitil for Pulmonary Arterial Hypertension?
• Which are the late-stage emerging therapies under development for the treatment of Pulmonary Arterial Hypertension?

Table of Contents

1. Report Introduction

2. Treprostinil palmitil Overview in Pulmonary Arterial Hypertension

• 2.1 Product Detail
• 2.2 Clinical Development
  • 2.2.1 Clinical Studies
  • 2.2.2 Clinical Trials Information
• 2.3 Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)*

5. Treprostinil palmitil Market Assessment

• 5.1 Market Outlook of Treprostinil palmitil in Pulmonary Arterial Hypertension
• 5.2 7MM Market Analysis
  • 5.2.1 Market Size of Treprostinil palmitil in the 7MM for Pulmonary Arterial Hypertension
• 5.3 Country-wise Market Analysis
  • 5.3.1 Market Size of Treprostinil palmitil in the United States for Pulmonary Arterial Hypertension
  • 5.3.2 Market Size of Treprostinil palmitil in Germany for Pulmonary Arterial Hypertension
  • 5.3.3 Market Size of Treprostinil palmitil in France for Pulmonary Arterial Hypertension
  • 5.3.4 Market Size of Treprostinil palmitil in Italy for Pulmonary Arterial Hypertension
  • 5.3.5 Market Size of Treprostinil palmitil in Spain for Pulmonary Arterial Hypertension
  • 5.3.6 Market Size of Treprostinil palmitil in the United Kingdom for Pulmonary Arterial Hypertension
  • 5.3.7 Market Size of Treprostinil palmitil in Japan for Pulmonary Arterial Hypertension

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1 Bibliography
• 8.2 Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Option